Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

VRTX 10.18.2024

Full Press ReleaseSEC FilingsOur VRTX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43rd Annual J.P. Morgan Healthcare Conference
  • 01.13.2025 - CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones
  • 01.12.2025 - Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

Recent Filings

  • 01.17.2025 - 4 Statement of changes in beneficial ownership of securities

-- Phase 3 abstract selected for presentation in “Best Abstract” session --

BOSTON--(BUSINESS WIRE)--Oct. 18, 2024--Vertex Pharmaceuticals Incorporated(Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on suzetrigine, an investigational, oral, highly selective NaV1.8 pain signal inhibitor for the treatment of moderate-to-severe acute pain, at the annual meeting of theAmerican Society of Anesthesiologists(ASA), taking place fromOctober 18-22, 2024inPhiladelphia, Pennsylvania.

  • Abstract A1187 — “Randomized, Placebo-Controlled, Phase 3 Trials of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor for Treatment of Acute Pain After Abdominoplasty or Bunionectomy” will be presented as an oral presentation onSunday, October 20, during the “Best Abstract” session, which runs from8:00-11:00 a.m. ET, as well as the Education session which runs onMonday, October 21, from1:30-2:30 p.m. ET.
  • Abstract A2074 — “A Phase 3, Single-Arm Study of Suzetrigine, a Non-Opioid, Pain Signal Inhibitor For Treatment of Acute Pain From Surgical and Non-surgical Conditions” will be presented in a poster session onSaturday, October 19, from10:00-11:30 a.m. ET.

This will be the first time the suzetrigine Phase 3 data will be presented to the medical community following theJanuary 2024announcement that the Phase 3 trials were positive. The Phase 3 program included two randomized, double-blind, placebo-controlled trials, one following abdominoplasty surgery and one following bunionectomy surgery, as well as a single arm safety and effectiveness study which enrolled patients with a broad range of surgical and non-surgical pain conditions. Results from all three studies demonstrate compelling and consistent efficacy and safety across multiple acute pain conditions and settings.

“Our goal in developing suzetrigine is to deliver the first non-opioid acute pain treatment in more than two decades and to change the paradigm of pain management as we know it,” saidCarmen Bozic, M.D., Executive Vice President,Global Medicines Developmentand Medical Affairs, and Chief Medical Officer atVertex. “We are very pleased to have these Phase 3 data selected for presentation in the “Best Abstract” session at the annual ASA meeting and the opportunity to share these important results in this forum.”

“For decades, pain treatment options have been extremely limited,” saidTodd Bertoch, M.D., a practicing anesthesiologist and researcher, CEO of CenExel JBR Clinical Research inSalt Lake City, and lead presenter for the suzetrigine Phase 3 data. “This research has brought about a renewed optimism for the future of pain management, and I’m looking forward to sharing our findings with the ASA community. Suzetrigine offers the potential to fill the critically important treatment gap between opioids and other currently available therapies that have either limited efficacy and/or poor tolerability.”

Suzetrigine Program Updates

The company continues to progress its peripheral neuropathic pain (PNP) clinical development program for suzetrigine and has initiated its Phase 3 pivotal program of suzetrigine in patients with painful diabetic peripheral neuropathy (DPN). Additionally,Vertexremains on track to share results in late 2024 from its Phase 2 study of suzetrigine in painful lumbosacral radiculopathy (LSR).

Investor Event and Webcast

Vertexwill host an investor event onSunday, October 20, 2024, at6:00 p.m. ETinPhiladelphiato discuss suzetrigine and the Phase 3 clinical trial results in acute pain. A live webcast of the presentation and Q&A portions can be accessed through the Investor Relations section ofVertex's website athttps://investors.vrtx.com/. An archived webcast will be available on the company's website.

About Acute Pain

Acute pain is a disabling condition and is defined as pain lasting less than 3 months. It is estimated that over 80 million people are prescribed a medicine for acute pain every year in theU.S.Due to limited treatment options, there is an unmet need in acute pain management to improve the patient experience and reduce the economic and societal burden.

About Suzetrigine

Suzetrigine is an investigational oral, highly selective pain signal inhibitor that is selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that is selectively expressed in peripheral pain-sensing neurons (nociceptors), where its role is to transmit pain signals (action potentials). Vertex’s approach is to selectively inhibit NaV1.8 using small molecules with the objective of creating a new class of pain signal inhibitors that have the potential to provide effective relief of pain without the limitations of currently available therapies, including the addictive potential of opioids. Suzetrigine has demonstrated a favorable benefit/risk profile in multiple Phase 2 and Phase 3 studies in patients with moderate-to-severe acute pain and has been granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain in theU.S.It is currently under priority review by the FDA for the treatment of moderate-to-severe acute pain with a Prescription Drug User Fee Act (PDUFA) target action date ofJanuary 30, 2025.Vertexis also evaluating suzetrigine in peripheral neuropathic pain (PNP) with the goal of pursuing a broad PNP label.Vertexrecently initiated a Phase 3 pivotal program of suzetrigine in patients with painful diabetic peripheral neuropathy (DPN) and has completed enrollment in its Phase 2 study of suzetrigine in painful lumbosacral radiculopathy (LSR) — both are PNP conditions. Suzetrigine is investigational and has not been approved by any health authority.

AboutVertex

Vertexis a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases.Vertexalso has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including acute and neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes and myotonic dystrophy type 1.

Vertexwas founded in 1989 and has its global headquarters inBoston, with international headquarters inLondon. Additionally, the company has research and development sites and commercial offices inNorth America,Europe,Australia,Latin Americaand theMiddle East.Vertexis consistently recognized as one of the industry's top places to work, including 14 consecutive years onScience magazine'sTop Employers list and one of Fortune’s 100 Best Companies to Work For. For company updates and to learn more aboutVertex's history of innovation, visitwww.vrtx.comor follow us onLinkedIn,Facebook,Instagram,YouTubeandX.

Special Note Regarding Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements byCarmen Bozic, M.D., andTodd Bertoch, M.D., in this press release, and statements about Vertex’s plans to present pivotal Phase 3 data on suzetrigine at ASA, Vertex’s beliefs about the potential benefits of suzetrigine, plans to continue to progress the PNP clinical development program for suzetrigine and the goal of a broad PNP label, Vertex’s plans to host an investor event to discuss suzetrigine and Phase 3 results in acute pain, and plans to share results from the Phase 2 study of suzetrigine in LSR in late 2024. WhileVertexbelieves the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from a limited number of patients may not be indicative of final clinical trial results, that clinical trial data might not be available on the expected timeline, that data from the company's research and development programs may not support registration or further development of its compounds due to safety, efficacy, and other risks listed under the heading “Risk Factors” inVertex's most recent annual report and subsequent quarterly reports filed with theSecurities and Exchange Commissionatwww.sec.govand available through the company's website atwww.vrtx.com. You should not place undue reliance on these statements, or the scientific data presented.Vertexdisclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241017447532/en/

Vertex Pharmaceuticals IncorporatedInvestors:InvestorInfo@vrtx.comSusie Lisa, CFA: +1 617-341-6108orMiroslava Minkova: +1 617-341-6135Media:mediainfo@vrtx.comorInternational: +44 20 3204 5275orU.S.: 617-341-6992orHeather Nichols: +1 617-839-3607

Source:Vertex Pharmaceuticals Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com